Skip to main content
. Author manuscript; available in PMC: 2022 Jul 16.
Published in final edited form as: Lancet HIV. 2018 Jan 16;5(4):e172–e180. doi: 10.1016/S2352-3018(18)30003-1

Figure 2.

Figure 2.

Rates of the START primary endpoint (serious AIDS or serious non-AIDS conditions including all-cause death) per 100 person-years, and absolute risk reduction (ARR) in the immediate versus the deferred ART groups within subgroups formed by baseline characteristics.

The p-value is for a bootstrap test for heterogeneity of the ARR across subgroups.